The first patient has been treated in the Phase I trial with MCY-M11 (antimesothelin, CARMA-hMeso), the novel chimeric antigen receptor (CAR) cell therapy developed by MaxCyte.
10 Oct 2018
Major milestone achieved, as first patient is treated with a CARMA product
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Major milestone achieved, as first patient is treated with a CARMA product
MaxCyte, Inc. (MXCT:LON) | 313 0 0.0% | Mkt Cap: 325.9m
- Published:
10 Oct 2018 -
Author:
Mick Cooper PhD -
Pages:
2
The first patient has been treated in the Phase I trial with MCY-M11 (antimesothelin, CARMA-hMeso), the novel chimeric antigen receptor (CAR) cell therapy developed by MaxCyte.